Emerging new anticancer therapies in 2013.
Carlos Gomez-Roca1, Jean-Pierre Delord
1Departement of Medical Oncology, Institut Claudius Regaud, Toulouse, France.
2013 saw significant advances in anticancer therapies, including new immunotherapies and targeted agents. These developments promise improved treatments for various cancers, particularly those with oncogene addiction.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- 2013 was a pivotal year for novel anticancer agent development.
- Advances were presented across major international oncology meetings and peer-reviewed journals.
Purpose of the Study:
- To provide an update on the most significant advances in new anticancer therapies reported in 2013.
- To highlight key developments in targeted therapies and immunotherapies.
Main Methods:
- Review of presentations and publications from 2013.
- Focus on emerging anticancer agents and therapeutic strategies.
Main Results:
- Highlighting advances in cancer immunotherapy.
- Discussing combinations of targeted agents to overcome drug resistance.
- Reviewing second and third-generation targeted agents for oncogene addiction.
- Examining new antibody-drug conjugates for epithelial tumors.
Conclusions:
- Emerging therapies from 2013 are expected to lead to new approvals.
- Future treatments will likely include novel immunotherapies for diverse tumor types.
- Second-generation agents will be crucial for overcoming resistance in oncogene-addicted tumors.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy